Top

BY Ron Gilmore

Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic lymphoblastic leukemia , two blood cancers that often result in relapse after first treatments. Initial findings for both will be presented this weekend at the 61st American Society of Hematology Annual Meeting & Exposition (ASH).

Abstract 125: Results of a phase II study of obinutuzumab in combination...

BY Ron Gilmore

The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid...

BY Ron Gilmore

A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET...

BY Ron Gilmore

Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center have discovered that removing an unwanted element from a protein known to suppress the immune system may eventually help clinicians better observe which cancer patients will benefit by treatment with immune checkpoint blockades.

Heng-Huan Lee, Ph.D., a postdoctoral fellow and Ying-Nai Wang,...

Glycans attach to the PD-L1 protein on tumors, making it hard to detect. MD Anderson researchers have found that purging glycans makes PD-L1 easier to find and accurately assess. Image courtesy of Cancer Cell.

BY Ron Gilmore

Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous...

BY Ron Gilmore

A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of...

BY Ron Gilmore

Whether it is new clinical trials for pediatric cancers or programs designed to increase access to smoking cessation programs for low-income...

BY Ron Gilmore

Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved in November...

BY Ron Gilmore

MD Anderson researchers have discovered that a protein called angiogenin (ANG) serves as a potential biomarker useful for stratifying pancreatic...

BY Ron Gilmore

Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according...